Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen KANJINTI (trastuzumab-anns by Year
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M) ($M)
Amgen KANJINTI (trastuzumab-anns: $109M in FY2023, down 57.6% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| KANJINTI — U.S. | 109 | (58) | % | 257 | (46) | % | 479”
Source: Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 109 | -57.6% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 257 | -46.3% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 479 | +0.8% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 475 | +302.5% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 118 | – | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
Cite this data
StockData. (2026). Amgen KANJINTI (trastuzumab-anns ($M), annual FY2019–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kanjinti-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.